Joerg Boecker1, Bernd Feyerabend2, Katharina Tiemann3, Igor Buchwalow3, Kim C Wagner4, Karl J Oldhafer4, Julia Andruszkow5, Thies Daniels6, Dorthe Boessow6, Werner Boecker7,8, Ulf Peter Neumann1. 1. From the Department of Surgery and Transplantation, University Hospital RWTH Aachen, Aachen. 2. Department of Pathology, Asklepios Clinic Barmbek. 3. Institute of Hematopathology. 4. Department of Surgery, Asklepios Clinic Barmbek, Hamburg. 5. Department of Pathology, University Hospital RWTH Aachen, Aachen. 6. Department of Surgery, Albertinen-Hospital, Hamburg. 7. Gerhard-Domagk Institute of Pathology, University of Muenster, Muenster. 8. Gerhard Seifert Reference-Center for Oral-, Gyneco-, and Breast Pathology, Hamburg, Germany.
Abstract
OBJECTIVES: Information of the clinicopathological characteristics and outcome data of patients with adenosquamous carcinoma of the pancreas (ASCAP) remains limited. This study's aim is to describe the clinical, pathological, and molecular characteristics of 25 resected ASCAPs. METHODS: Of all 25 cases, patient characteristics, follow-up data, and pathological/immunohistological features were reviewed and analyzed. RESULTS: In this 3-institutional retrospective analysis of 562 pancreatic cancer patients, we identified 25 cases with histologically confirmed ASCAP (4.4%). Follow-up was available in 21 ASCAP and 50 pancreatic ductal adenocarcinoma control patients with a median overall survival of 8.2 and 21 months, respectively. Age, tumor size, localization in the tail, lymph node status, and resection margin seem to be the most significant factors of survival in our ASCAP cohort. In contrast to pancreatic ductal adenocarcinoma, positive expression of p63, keratins K5/14, and the epidermal growth factor receptor are a robust marker profile of these tumors. CONCLUSIONS: Adenosquamous carcinoma of the pancreas comprises a group of neoplasms in which stage and adverse morphological features contribute to its bad prognosis. Further work must be pursued to improve detection and treatment options to reduce mortality. Specifically, differences in biology might become a target for the development of possible therapies.
OBJECTIVES: Information of the clinicopathological characteristics and outcome data of patients with adenosquamous carcinoma of the pancreas (ASCAP) remains limited. This study's aim is to describe the clinical, pathological, and molecular characteristics of 25 resected ASCAPs. METHODS: Of all 25 cases, patient characteristics, follow-up data, and pathological/immunohistological features were reviewed and analyzed. RESULTS: In this 3-institutional retrospective analysis of 562 pancreatic cancerpatients, we identified 25 cases with histologically confirmed ASCAP (4.4%). Follow-up was available in 21 ASCAP and 50 pancreatic ductal adenocarcinoma control patients with a median overall survival of 8.2 and 21 months, respectively. Age, tumor size, localization in the tail, lymph node status, and resection margin seem to be the most significant factors of survival in our ASCAP cohort. In contrast to pancreatic ductal adenocarcinoma, positive expression of p63, keratins K5/14, and the epidermal growth factor receptor are a robust marker profile of these tumors. CONCLUSIONS:Adenosquamous carcinoma of the pancreas comprises a group of neoplasms in which stage and adverse morphological features contribute to its bad prognosis. Further work must be pursued to improve detection and treatment options to reduce mortality. Specifically, differences in biology might become a target for the development of possible therapies.
Authors: André Fehr; Sarah Werenicz; Pietro Trocchi; Markus Falk; Reinhard E Friedrich; Angelika Stammler; Andreas Stang; Florian Oesterling; Laura Khil; Göran Stenman; Werner Böcker; Katharina Tiemann; Thomas Löning Journal: Virchows Arch Date: 2021-07-07 Impact factor: 4.064